
    
      To evaluate the duration of remission, disease free survival and 2-year survival of R-COMP in
      first line therapy of elderly patients with advanced aggressive NHL.

      To evaluate the tolerability of R-COMP in first line therapy of elderly patients with
      advanced aggressive NHL.
    
  